[go: up one dir, main page]

ES538172A0 - Procedimiento para la obtencion de derivados de etilendiamina sustituidos - Google Patents

Procedimiento para la obtencion de derivados de etilendiamina sustituidos

Info

Publication number
ES538172A0
ES538172A0 ES538172A ES538172A ES538172A0 ES 538172 A0 ES538172 A0 ES 538172A0 ES 538172 A ES538172 A ES 538172A ES 538172 A ES538172 A ES 538172A ES 538172 A0 ES538172 A0 ES 538172A0
Authority
ES
Spain
Prior art keywords
ethylendiamine
derivatives
procedure
obtaining substituted
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES538172A
Other languages
English (en)
Other versions
ES8701142A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES538172A0 publication Critical patent/ES538172A0/es
Publication of ES8701142A1 publication Critical patent/ES8701142A1/es
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • C07D211/58Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0227Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES538172A 1983-12-01 1984-11-30 Procedimiento para la obtencion de derivados de etilendiamina sustituidos Expired ES8701142A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH643683 1983-12-01

Publications (2)

Publication Number Publication Date
ES538172A0 true ES538172A0 (es) 1986-11-16
ES8701142A1 ES8701142A1 (es) 1986-11-16

Family

ID=4309613

Family Applications (1)

Application Number Title Priority Date Filing Date
ES538172A Expired ES8701142A1 (es) 1983-12-01 1984-11-30 Procedimiento para la obtencion de derivados de etilendiamina sustituidos

Country Status (6)

Country Link
EP (1) EP0144290A3 (es)
JP (1) JPS60136595A (es)
AU (1) AU3609484A (es)
DK (1) DK571484A (es)
ES (1) ES8701142A1 (es)
GR (1) GR81124B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI88400C (fi) * 1984-08-06 1993-05-10 Upjohn Co Foerfarande foer framstaellning av renin inhiberande peptider
WO1991006561A1 (en) * 1989-10-27 1991-05-16 The Upjohn Company Method for treating hiv and other retroviruses and compounds useful therefor
FR2711990B1 (fr) * 1993-11-05 1995-12-08 Exsymol Sa Produit pseudodipeptide possédant un groupement imidazole, et applications thérapeutiques, cosmétologiques et agroalimentaires.
WO1996004244A1 (en) * 1994-08-05 1996-02-15 Warwick International Group Limited Bleach activators
JP4484897B2 (ja) * 1995-12-08 2010-06-16 生化学工業株式会社 アミノアルコール誘導体の製造方法
GB9727123D0 (en) * 1997-12-22 1998-02-25 Int Centre Genetic Eng & Bio Synthesis of diamines
WO2001002363A2 (en) * 1999-07-06 2001-01-11 Vertex Pharmaceuticals Incorporated N-substituted glycine derivatives
WO2005113582A1 (en) * 2004-05-22 2005-12-01 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
RU2433999C2 (ru) * 2005-01-26 2011-11-20 Аллерган, Инк. Амиды 3-арил-3-гидрокси-2-аминопропионовой кислоты, амиды 3-гетероарил-3-гидрокси-2-аминопропионовой кислоты и родственные соединения, обладающие обезболивающим и/или иммуностимулирующим действием
HUE026057T2 (en) 2006-05-09 2016-05-30 Genzyme Corp Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis
EP2594564B1 (en) * 2007-05-31 2016-09-28 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
KR20150085139A (ko) 2007-10-05 2015-07-22 젠자임 코포레이션 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
EP2320886B1 (en) 2008-07-28 2017-06-28 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP3078373A1 (en) 2008-10-03 2016-10-12 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitor
EP3678700B1 (en) * 2017-09-05 2024-06-19 Merck Sharp & Dohme LLC Compounds for reducing the viscosity of biological formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198398A (en) * 1977-07-12 1980-04-15 Derek Hudson Enkephalin analogues
US4145337A (en) * 1977-10-11 1979-03-20 Hoffmann-La Roche Inc. Aminoethylglycine containing polypeptides
GB2058077B (en) * 1979-06-08 1983-03-09 Szelke M Enkephalin analogues
NO812612L (no) * 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
CA1245217A (en) * 1981-12-10 1988-11-22 Joshua S. Boger Renin inhibitory peptides having phe su13 xx deletion
FI843837L (fi) * 1983-02-07 1984-09-28 Ferring Ab Enzyminhibitorer.
US4661473A (en) * 1984-03-27 1987-04-28 Merck & Co., Inc. Renin inhibitors containing peptide isosteres

Also Published As

Publication number Publication date
GR81124B (en) 1985-03-26
JPS60136595A (ja) 1985-07-20
DK571484D0 (da) 1984-11-30
DK571484A (da) 1985-06-02
EP0144290A3 (de) 1987-05-27
ES8701142A1 (es) 1986-11-16
EP0144290A2 (de) 1985-06-12
AU3609484A (en) 1985-06-06

Similar Documents

Publication Publication Date Title
ES537830A0 (es) Procedimiento para la obtencion de derivados de 5-amino-4-hidroxivalerilo sustituidos
ES555048A0 (es) Procedimiento para la obtencion de derivados de azolilmetil-ciclopropilcarbinol sustituido
ES529282A0 (es) Procedimiento para preparar derivados de tiazol
ES536138A0 (es) Procedimiento para preparar derivados azolicos
ES538172A0 (es) Procedimiento para la obtencion de derivados de etilendiamina sustituidos
ES533538A0 (es) Procedimiento para la obtencion de tetrahidropiridazinonas
ES539255A0 (es) Procedimiento para preparar derivados de isoquinoleina
ES556156A0 (es) Procedimiento para la obtencion de derivados de la 13-beta-milbemicina
ES542947A0 (es) Procedimiento para la obtencion de derivados piperazinicos
MX157033A (es) Procedimiento para preparar derivados de pirrolo quinoleina
ES543991A0 (es) Procedimiento para la obtencion de derivados de indol
ES539204A0 (es) Procedimiento para la obtencion de imidazoles sustituidos
ES529916A0 (es) Procedimiento para la obtencion de derivados de feniletilamina
ES535704A0 (es) Procedimiento para la obtencion de derivados de piridinio
ES534377A0 (es) Procedimiento para preparar derivados de antraciclina
MX7403E (es) Procedimiento para preparar derivados de benzoil-ureas
ES528654A0 (es) Procedimiento para la obtencion de derivados de tetrahidrocarbazol
ES533988A0 (es) Procedimiento para la obtencion de mercaptocarboxilamidas
ES527054A0 (es) Procedimiento para la obtencion de derivados bis-quinazolinicos
ES549383A0 (es) Procedimiento para la obtencion de derivados de 2-aminometil-2-penem.
ES530626A0 (es) Procedimiento para preparar derivados de ciano-2-imidazopiridina
ES545599A0 (es) Procedimiento para la obtencion de derivados de ciclohexeno-na
ES531837A0 (es) Procedimiento para la obtencion de derivados de azoliletil-bencil-eter.
ES537129A0 (es) Procedimiento para la obtencion de iodacetamidas
ES532142A0 (es) Procedimiento para preparar derivados acilaminofenolicos